By Matt Grossman

 

Gilead Sciences Inc.'s Truvada drug has been approved by the China National Medical Products Administration for pre-exposure prophylaxis against sexually acquired HIV-1, Gilead said Tuesday.

Truvada is the first medication approved for HIV prevention in China, Gilead said. It had already been approved for that use in the United States. In China, Truvada was previously approved as a treatment for HIV-1 infection in combination with other antriretroviral medications.

Between January and October 2019, 131,000 new HIV infections were reported in China, with sexual transmission the primary mode of infection, Gilead said, citing data from the China National Health Commission.

 

Write to Matt Grossman at matt.grossman@wsj.com

 

(END) Dow Jones Newswires

August 11, 2020 08:43 ET (12:43 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2020 to Sep 2020 Click Here for more Gilead Sciences Charts.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2019 to Sep 2020 Click Here for more Gilead Sciences Charts.